News

"Retinal vein occlusion is a common retinal vascular disorder with an estimated 16.4 million people affected worldwide, and it is a severe disease which is potentially blinding if

The in-clinic, randomized, placebo-controlled, double-blind Phase IIa trial will evaluate patients with epilepsy using the intermittent photo-stimulation model. The trial’s primary aim is to evaluate the safety and

Bexsero is the only meningitis B vaccine approved in the US with a two-dose regimen and a flexible dosing schedule[1]. As part of the accelerated approval process, Novartis

The OS results in 123 patients demonstrated that aldoxorubicin-treated patients demonstrated a 27 percent reduction in the risk of death compared to patients treated with doxorubicin (HR 0.73:

The patent is entitled " Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue ". The claims of the granted patent cover both a specified population of

This partnership is publicized just shortly after the strategic collaboration that was reached between WCCT Global and the NIAID for influenza challenge research. This agreement between DynPort and

Autolus is founded upon the work of Dr Martin Pule, an academic clinical haematologist and thought-leader in T-cell engineering. Syncona has committed £30m to Autolus in a Series

Prevenar 13 is currently approved in Europe for the prevention of invasive pneumococcal disease (IPD) in the same population. he CHMP’s positive opinion will now be reviewed by

Currently, the company is conducting a Phase Ib/II trial of APR-246 in combination with carboplatin (AUC 5) and pegylated doxorubicin (30 mg/m2), a second line standard of care